Shares of Nuvectra Corp. (NASDAQ:NVTR) have earned a consensus broker rating score of 2.00 (Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold recommendation and one has assigned a strong buy recommendation to the company.
Brokerages have set a 12 month consensus price target of $11.00 for the company and are expecting that the company will post ($0.88) EPS for the current quarter, according to Zacks. Zacks has also assigned Nuvectra Corp. an industry rank of 105 out of 265 based on the ratings given to related companies.
A number of equities analysts recently issued reports on NVTR shares. Piper Jaffray Cos. reissued a “neutral” rating and issued a $10.00 price objective (down from $12.00) on shares of Nuvectra Corp. in a report on Saturday, August 13th. B. Riley initiated coverage on Nuvectra Corp. in a research note on Thursday, September 15th. They set a “buy” rating and a $12.00 price target for the company.
Nuvectra Corp. (NASDAQ:NVTR) opened at 6.33 on Friday. The firm’s market capitalization is $65.05 million. Nuvectra Corp. has a 12-month low of $4.02 and a 12-month high of $11.64. The stock has a 50 day moving average price of $6.69 and a 200-day moving average price of $7.35.
Nuvectra Corp. (NASDAQ:NVTR) last issued its quarterly earnings data on Wednesday, August 10th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.28. The business earned $2.50 million during the quarter, compared to the consensus estimate of $2.40 million. Nuvectra Corp.’s revenue for the quarter was up 66.7% on a year-over-year basis. On average, equities research analysts forecast that Nuvectra Corp. will post ($3.37) EPS for the current year.
A hedge fund recently bought a new stake in Nuvectra Corp. stock. FNY Managed Accounts LLC purchased a new position in shares of Nuvectra Corp. (NASDAQ:NVTR) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 56,178 shares of the company’s stock, valued at approximately $389,000. FNY Managed Accounts LLC owned approximately 0.55% of Nuvectra Corp. as of its most recent SEC filing. 64.49% of the stock is currently owned by hedge funds and other institutional investors.
About Nuvectra Corp.
Nuvectra Corporation, formerly QIG Group, LLC, is a neurostimulation company. The Company is focused on the development and commercialization of a neurostimulation technology platform, which is used for the treatment of various disorders through stimulation of tissues associated with the nervous system.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nuvectra Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra Corp. and related companies with MarketBeat.com's FREE daily email newsletter.